Financials Shanghai General Healthy Information and Technology Co., Ltd.

Equities

End-of-day quote Shanghai S.E. Other stock markets 06:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
32.1 ^CNY	-1.83%		-10.18%	-23.10%

Apr. 29	Shanghai General Healthy Information and Technology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 29	Shanghai General Healthy Information and Technology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	3,826	4,931	4,094	5,677	4,366	-	-
Enterprise Value (EV) ¹	3,826	4,931	4,094	5,677	4,366	4,366	4,366
P/E ratio	29.9 x	42.2 x	35.4 x	94.9 x	34.5 x	25 x	23.8 x
Yield	-	-	0.3%	0.24%	0.28%	0.28%	-
Capitalization / Revenue	-	10.1 x	12.7 x	18.5 x	11.5 x	8.56 x	8.57 x
EV / Revenue	-	10.1 x	12.7 x	18.5 x	11.5 x	8.56 x	8.57 x
EV / EBITDA	-	34.6 x	30.2 x	77.4 x	33.3 x	20.6 x	23.1 x
EV / FCF	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-
Price to Book	-	5.47 x	4.07 x	5.39 x	3.7 x	3.13 x	2.93 x
Nbr of stocks (in thousands)	136,000	136,000	136,000	136,000	136,000	-	-
Reference price ²	28.13	36.26	30.10	41.74	32.10	32.10	32.10
Announcement Date	4/19/21	3/9/22	4/28/23	4/29/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	-	489.8	322.4	307.6	380.7	510.3	509.4
EBITDA ¹	-	142.4	135.6	73.38	131.3	212.3	188.6
EBIT ¹	-	143.8	132.1	67.64	145	213.9	209.3
Operating Margin	-	29.36%	40.97%	21.99%	38.09%	41.91%	41.09%
Earnings before Tax (EBT) ¹	-	143.8	132	67.85	144.9	213.9	209.3
Net income ¹	95.74	117.6	115.7	60	127.1	174.5	183.6
Net margin	-	24.02%	35.89%	19.51%	33.38%	34.2%	36.03%
EPS ²	0.9400	0.8600	0.8500	0.4400	0.9300	1.285	1.350
Free Cash Flow	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-
Dividend per Share ²	-	-	0.0900	0.1000	0.0900	0.0900	-
Announcement Date	4/19/21	3/9/22	4/28/23	4/29/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	-	13.6%	12.1%	5.82%	11.4%	12.8%	13.1%
ROA (Net income/ Total Assets)	-	-	9.94%	-	10.3%	11.3%	-
Assets ¹	-	-	1,164	-	1,234	1,545	-
Book Value Per Share ²	-	6.630	7.390	7.740	8.680	10.30	11.00
Cash Flow per Share ²	-	0.4000	-0.2700	-0.2600	2.980	2.300	1.140
Capex ¹	-	81.4	66.7	36.4	38.1	35.3	30.6
Capex / Sales	-	16.61%	20.7%	11.84%	10%	6.92%	6%
Announcement Date	4/19/21	3/9/22	4/28/23	4/29/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

32.1 CNY

Average target price

40.18 CNY

Spread / Average Target

+25.17%

	1st Jan change	Capi.
SHANGHAI GENERAL HEALTHY INFORMATION AND TECHNOLOGY CO., LTD.	-23.10%	604M
ABBOTT LABORATORIES	-5.43%	181B
MEDTRONIC PLC	+4.30%	114B
BECTON, DICKINSON AND COMPANY	-3.09%	68.29B
DEXCOM, INC.	+5.86%	52.24B
CENCORA, INC.	+8.15%	44.3B
HOYA CORPORATION	+7.52%	42.73B
METTLER-TOLEDO INTERNATIONAL, INC.	+25.54%	32.52B
TERUMO CORPORATION	+17.85%	26.02B
WEST PHARMACEUTICAL SERVICES, INC.	+1.00%	25.91B